Free Trial

Artiva Biotherapeutics (ARTV) Competitors

Artiva Biotherapeutics logo
$1.78 +0.04 (+2.01%)
As of 11:22 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ARTV vs. ACRS, BIOA, MOLN, ALEC, VTYX, LXEO, THTX, BDTX, ALTS, and LYEL

Should you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Aclaris Therapeutics (ACRS), BioAge Labs (BIOA), Molecular Partners (MOLN), Alector (ALEC), Ventyx Biosciences (VTYX), Lexeo Therapeutics (LXEO), Theratechnologies (THTX), Black Diamond Therapeutics (BDTX), ALT5 Sigma (ALTS), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.

Artiva Biotherapeutics vs. Its Competitors

Aclaris Therapeutics (NASDAQ:ACRS) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

98.3% of Aclaris Therapeutics shares are held by institutional investors. 6.4% of Aclaris Therapeutics shares are held by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aclaris Therapeutics presently has a consensus target price of $8.71, indicating a potential upside of 446.35%. Artiva Biotherapeutics has a consensus target price of $17.80, indicating a potential upside of 902.82%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Aclaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclaris Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Artiva Biotherapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Aclaris Therapeutics had 4 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 4 mentions for Aclaris Therapeutics and 0 mentions for Artiva Biotherapeutics. Aclaris Therapeutics' average media sentiment score of 0.77 beat Artiva Biotherapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aclaris Therapeutics Positive
Artiva Biotherapeutics Neutral

Artiva Biotherapeutics has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -732.42%. Aclaris Therapeutics' return on equity of -30.73% beat Artiva Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aclaris Therapeutics-732.42% -30.73% -22.74%
Artiva Biotherapeutics N/A -75.95%-39.51%

Artiva Biotherapeutics has lower revenue, but higher earnings than Aclaris Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclaris Therapeutics$18.72M9.23-$132.07M-$1.39-1.15
Artiva BiotherapeuticsN/AN/A-$65.37MN/AN/A

Summary

Aclaris Therapeutics beats Artiva Biotherapeutics on 9 of the 13 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ARTV vs. The Competition

MetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$43.49M$2.97B$5.59B$9.00B
Dividend YieldN/A2.44%5.25%4.03%
P/E RatioN/A21.5027.5420.18
Price / SalesN/A255.29415.83171.78
Price / CashN/A41.8337.0657.97
Price / Book0.237.858.105.61
Net Income-$65.37M-$55.05M$3.17B$248.59M
7 Day Performance7.90%5.25%3.33%4.67%
1 Month Performance-14.66%3.68%3.54%7.18%
1 Year PerformanceN/A5.37%33.62%21.21%

Artiva Biotherapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARTV
Artiva Biotherapeutics
2.0561 of 5 stars
$1.78
+2.0%
$17.80
+902.8%
N/A$43.49MN/A0.0081
ACRS
Aclaris Therapeutics
2.6353 of 5 stars
$1.46
+1.4%
$9.71
+565.4%
+22.2%$155.93M$18.72M-1.05100Analyst Forecast
Gap Up
BIOA
BioAge Labs
N/A$4.18
-2.3%
N/AN/A$153.44MN/A0.00N/ANews Coverage
MOLN
Molecular Partners
2.807 of 5 stars
$3.61
-4.0%
$12.00
+232.4%
-44.3%$151.81M$2.23M-1.88180Gap Down
ALEC
Alector
4.0616 of 5 stars
$1.44
-4.6%
$4.00
+177.8%
-65.4%$150.99M$100.56M-1.14270News Coverage
VTYX
Ventyx Biosciences
2.4007 of 5 stars
$2.04
-1.9%
$10.00
+390.2%
+2.6%$148.01MN/A-1.1730
LXEO
Lexeo Therapeutics
2.2775 of 5 stars
$4.54
+2.0%
$16.60
+265.6%
-72.5%$147.73M$650K-1.3858High Trading Volume
THTX
Theratechnologies
N/A$3.17
-0.9%
N/A+105.2%$147.14M$85.87M-39.63140News Coverage
Earnings Report
High Trading Volume
BDTX
Black Diamond Therapeutics
2.7253 of 5 stars
$2.50
-3.1%
$12.80
+412.0%
-47.3%$146.71MN/A41.6790
ALTS
ALT5 Sigma
0.0651 of 5 stars
$7.54
-8.4%
N/AN/A$143.65M$12.53M0.00170
LYEL
Lyell Immunopharma
2.5927 of 5 stars
$9.15
-5.6%
$15.00
+63.9%
-68.1%$143.49M$60K-0.37270

Related Companies and Tools


This page (NASDAQ:ARTV) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners